{"product_id":"zvra-swot-analysis","title":"(ZVRA) Zevra Therapeutics, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Credibility Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Zevra Therapeutics, Inc. SWOT Analysis summarizes what the company does, how its products are used, and presents a structured look at strengths, weaknesses, opportunities, and threats; the page already includes a real preview\/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use SWOT report for research, strategy, or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 FDA-approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has 2 FDA-approved products, AZSTARYS and APADAZ, which gives it commercial-stage proof, not just pipeline hope. That lowers dependence on a single clinical asset and shows the Company can move programs through FDA review and into the market. In FY2025, this approval base supports a more durable revenue mix and a clearer path to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary LAT platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics’ Ligand Activated Therapy platform turns known compounds into prodrugs, giving it a clear edge in drug design and lifecycle management. That lets the Company create new formulations and pursue new indications from one chemistry base, which can lower development risk versus starting from scratch.\u003c\/p\u003e\n\u003cp\u003eThis matters after MIPLYFFA, the Company’s FDA-approved NPC therapy, because LAT can extend value beyond a single launch. It also gives Zevra Therapeutics a repeatable way to build assets with better dosing or delivery traits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-disease and CNS focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. focuses on high-unmet-need CNS niches like idiopathic hypersomnia, narcolepsy, stimulant use disorder, and ADHD, which helps it build a sharper clinical and commercial position. These are small, specialized markets, but treatment options are still limited, so even modest uptake can matter. The company also had one FDA-approved product in 2025, which supports execution in targeted patient groups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhase II pipeline momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics has 2 Phase II assets, KP1077 for idiopathic hypersomnia and narcolepsy, and KP879 for stimulant use disorder. That mid-stage breadth gives the Company more than one shot at value creation, since positive Phase II data can support higher partnering, licensing, or valuation upside.\u003c\/p\u003e\n\u003cp\u003eFor a small biotech, multiple programs in the same stage can also spread clinical risk across different rare and underserved markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 Phase II programs\u003c\/li\u003e\n\u003cli\u003eKP1077: idiopathic hypersomnia, narcolepsy\u003c\/li\u003e\n\u003cli\u003eKP879: stimulant use disorder\u003c\/li\u003e\n\u003cli\u003eMore shots at value creation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and licensing base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has partnership and licensing ties with KVK-Tech, Inc. and Commave Therapeutics SA, which can widen development, manufacturing, and commercial reach without Zevra funding all steps itself. These deals also signal outside validation of Zevra Therapeutics, Inc. assets, since partners only commit when they see usable value. In biotech, that kind of third-party backing can matter as much as cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eوسع reach through partners\u003c\/li\u003e\n\u003cli\u003eLower internal capital load\u003c\/li\u003e\n\u003cli\u003eSignals asset validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra Enters FY2025 With 3 Approved Therapies and 2 Phase II Shots\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has 2 FDA-approved products, AZSTARYS and APADAZ, plus MIPLYFFA, so it enters FY2025 with 3 approved therapies and lower single-asset risk.\u003c\/p\u003e\n\u003cp\u003eIts Ligand Activated Therapy platform and 2 Phase II programs, KP1077 and KP879, give the Company repeatable shots at value creation in rare CNS markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 Strength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved products\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II assets\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore edge\u003c\/td\u003e\n\u003ctd\u003eLAT platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Zevra Therapeutics, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick SWOT snapshot for Zevra Therapeutics, Inc. to reduce strategic guesswork and speed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking each key Zevra Therapeutics claim to primary industry reports, patents, clinical trial registries, and regulatory data for fast, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited marketed portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has only 2 FDA-approved products, so revenue is still tied to a very small base. That makes execution on each launch, refill rate, and payer access critical, because one weak product can quickly hit total sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy reliance on clinical-stage assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics still leans on clinical-stage assets, with key pipeline programs in Phase II as of 2025, so future growth depends on trial success, safety, and FDA review. That keeps late-stage development risk high, because one failed readout can delay revenue by years. Even with its current commercial base, the company still needs clinical wins to expand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow therapeutic concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics is still concentrated in a few rare CNS and stimulant-linked programs, including its Niemann-Pick type C and urea-cycle disorder assets. That tight focus limits diversification, so one trial miss, label issue, or payer setback can hit more than one revenue stream. With only a small number of shots on goal, pipeline risk stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S.-centric business scope\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. still leans mainly on the U.S. for sales, so it misses out on ex-U.S. demand and currency diversification. That narrow scope also makes results more exposed to U.S. payer pressure, FDA timing, and coverage shifts, which can hit pricing and access fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S.-only focus limits global upside\u003c\/li\u003e\n\u003cli\u003eHigher exposure to payer cuts\u003c\/li\u003e\n\u003cli\u003eMore tied to FDA and CMS decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHistory of rebranding and transition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. was formerly KemPharm, Inc. and rebranded in February 2023, so the company is still paying the cost of a reset in market recognition. That kind of transition can force extra spending on brand education and slow trust-building with doctors, payers, and investors. It also signals that the business model is still proving whether its FY2025 growth can hold up after the name change.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFormer name: KemPharm, Inc.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRebrand completed: February 2023\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHigher brand-building and education needs\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePost-transition growth still needs proof\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Small Base and Phase II Pipeline Keep Risk High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. has just 2 FDA-approved products, so FY2025 revenue is still tied to a very small base. Its pipeline still leans on Phase II assets, which keeps clinical and FDA risk high. Sales are still mostly U.S.-based, so payer pressure and coverage shifts can hit fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage pipeline\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic mix\u003c\/td\u003e\n\u003ctd\u003eU.S.-heavy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eZevra Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is drawn directly from the full Zevra Therapeutics, Inc. report and highlights key strengths, weaknesses, opportunities, and threats to inform investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II upside for KP1077\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase II data for KP1077 could open a new revenue stream for Zevra Therapeutics, Inc. in idiopathic hypersomnia and narcolepsy, two sleep disorders with few approved options and strong unmet need. If results are positive, the program could broaden Zevra Therapeutics, Inc.'s CNS reach and help de-risk its LAT platform in another indication. That matters because one win can lift both pipeline value and partnering appeal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II upside for KP879\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKP879’s Phase II advance in stimulant use disorder could target a large unmet need: the 2024 National Survey on Drug Use and Health estimated 4.2 million people had stimulant misuse in the U.S. alone, and there are still no FDA-approved medicines for cocaine or methamphetamine use disorder. \u003c\/p\u003e\n\u003cp\u003eIf Zevra Therapeutics, Inc. shows a clear efficacy signal, KP879 could stand out in a market with few direct treatment options and high relapse risk. That kind of readout could support a differentiated franchise and new value beyond the current rare-disease base. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand AZSTARYS adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS is approved for ADHD in patients 6 years and older, giving Zevra a foothold in a U.S. market where about 7 million children 3-17 have ADHD. Broader prescribing, better payer coverage, and more physician familiarity can lift use. That matters because one approved brand can become a long-term commercial platform in a large, repeat-use market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroaden APADAZ utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAPADAZ is an immediate-release benzhydrocodone and acetaminophen tablet, and Zevra Therapeutics, Inc. can still widen awareness in short-term pain settings where clinicians want an oral option with clear dosing. If Zevra lifts prescribing in even a narrow slice of the acute-pain market, APADAZ can add a second revenue stream and reduce reliance on a small set of rare-disease assets. The product’s 12 mg\/325 mg strength gives it a clear, simple positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand use in acute-pain care\u003c\/li\u003e\n\u003cli\u003eTarget better prescriber awareness\u003c\/li\u003e\n\u003cli\u003eAdd portfolio diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLeverage rare-disease positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics can use rare-disease focus to target small patient groups with high unmet need, where premium pricing is more common. The rare-disease market serves about 300 million people worldwide across more than 7,000 diseases, so expertise in orphan-drug trials and niche sales channels can create a real edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need supports pricing power\u003c\/li\u003e\n\u003cli\u003eSpecialized trials build hard-to-copy know-how\u003c\/li\u003e\n\u003cli\u003eNiche channels can lower launch risk\u003c\/li\u003e\n\u003cli\u003eThat expertise helps future deals and licensing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra's CNS pipeline and brands could unlock a bigger growth story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. can grow through KP1077 and KP879 if Phase II data are strong, while AZSTARYS and APADAZ can add steady commercial cash flow. The upside is a broader CNS portfolio, more partnering leverage, and less dependence on rare-disease sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKP1077\u003c\/td\u003e\n\u003ctd\u003eIdiopathic hypersomnia, narcolepsy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKP879\u003c\/td\u003e\n\u003ctd\u003e4.2M stimulant misuse cases, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAZSTARYS\u003c\/td\u003e\n\u003ctd\u003eAbout 7M U.S. children with ADHD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPADAZ\u003c\/td\u003e\n\u003ctd\u003eSecond revenue stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKP1077 and KP879 are both in Phase II, so a single efficacy miss or safety issue could cut Zevra Therapeutics, Inc.'s pipeline value fast. For a small biopharma, that kind of setback can matter more than for large peers because it can hit valuation, funding access, and partner interest at the same time. With only early-to-midstage data in hand, the clinical trial failure risk stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter MIPLYFFA’s Sep. 20, 2024 FDA approval, Zevra Therapeutics, Inc. still faces full safety-and-efficacy review on every new program. Rare CNS assets and controlled-substance products often draw extra scrutiny, so timing can slip and labels can stay narrow. That leaves approval dates, use limits, and revenue timing uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition in ADHD and CNS markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAZSTARYS faces a crowded U.S. ADHD market, where about 7 million children aged 3 to 17 and 15.5 million adults are diagnosed with ADHD. That scale draws many stimulants and nonstimulants, so new launches can squeeze market share, slow physician adoption, and force price pressure.\u003c\/p\u003e\n\u003cp\u003eOther firms are also targeting sleep disorders and stimulant-related conditions, which raises the risk of direct competition across multiple CNS niches. For Zevra Therapeutics, Inc., even small shifts in formulary access can matter because prescribers often switch fast when rivals offer lower cost or easier dosing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eControlled-substance and safety risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. faces clear controlled-substance risk because APADAZ is a Schedule II opioid, and KP879 sits in a stimulant-sensitive area that draws tighter FDA and payer scrutiny. In the U.S., opioids were linked to about 81,000 overdose deaths in 2023, so even a small safety signal can trigger label changes, extra REMS-style controls, or slower prescribing.\u003c\/p\u003e\n\u003cp\u003eThat can hurt trust, limit uptake, and raise legal and compliance costs fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSchedule II drugs face strict monitoring\u003c\/li\u003e\n\u003cli\u003eSafety issues can cut prescription volume\u003c\/li\u003e\n\u003cli\u003eMisuse concerns can slow payer coverage\u003c\/li\u003e\n\u003cli\u003eAny label change can damage reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDependence on reimbursement and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. depends on payer coverage and fast patient access to turn approvals into sales. Rare-disease and specialty CNS drugs often face prior authorization, step edits, and high copays, so even a strong label can stall uptake. In a market where specialty medicines drive most U.S. drug spend, any pricing pushback can slow prescriptions and cap revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePayer controls can delay starts.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCopays can block fills.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePrice pressure can cut uptake.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZevra’s Pipeline and ADHD Market Face Major Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZevra Therapeutics, Inc. still faces high pipeline risk: KP1077 and KP879 are only in Phase II, so one trial miss can erase value fast. MIPLYFFA’s Sep. 20, 2024 FDA approval helps, but every new CNS or controlled-substance asset can face slower review and narrow labels. AZSTARYS also fights a crowded ADHD market with 7 million U.S. children and 15.5 million adults diagnosed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II pipeline\u003c\/td\u003e\n\u003ctd\u003eClinical failure risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eControlled substances\u003c\/td\u003e\n\u003ctd\u003eFDA, payer, misuse scrutiny\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD competition\u003c\/td\u003e\n\u003ctd\u003ePrice and share pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235189563657,"sku":"zvra-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/zvra-swot-analysis.webp?v=1785737022","url":"https:\/\/dcfanalyst.com\/products\/zvra-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}